Author:
Kira Jun-ichi,Itoyama Yasuto,Kikuchi Seiji,Hao Qi,Kurosawa Takayoshi,Nagato Kazuo,Tsumiyama Isao,von Rosenstiel Philipp,Zhang-Auberson Lixin,Saida Takahiko
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine
Reference24 articles.
1. US Food and Drug Administration (FDA): FDA approves first oral drug to reduce MS relapses Sep 22. 2010.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm
,
2. European Medicines Agency (EMA) Assessment report: Gilenya. Doc Ref: EMA/108602/2011. 17 February 2011.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf
,
3. Mitsubishi Tanabe Pharma Corporation: Approval for “IMUSERA® capsules 0.5mg”. Japan’s first once-daily oral dosing multiple sclerosis treatment (press release).
http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/eMTPC110926_IMU.pdf
,
4. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010, 9: 883-897. 10.1038/nrd3248.
5. Chun J, Hartung HP: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010, 33: 91-101. 10.1097/WNF.0b013e3181cbf825.
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献